BR0011555A - Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga - Google Patents

Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga

Info

Publication number
BR0011555A
BR0011555A BR0011555-0A BR0011555A BR0011555A BR 0011555 A BR0011555 A BR 0011555A BR 0011555 A BR0011555 A BR 0011555A BR 0011555 A BR0011555 A BR 0011555A
Authority
BR
Brazil
Prior art keywords
hiv
mutational profiles
reverse transcriptase
drug
drug resistance
Prior art date
Application number
BR0011555-0A
Other languages
English (en)
Inventor
Kurt Hertogs
Brendan Larder
Rudi Wilfried Jan Paulwels
Original Assignee
Virco Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco Nv filed Critical Virco Nv
Publication of BR0011555A publication Critical patent/BR0011555A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/912—Absidia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Patente de Invenção: "PERFIS MUTACIONAIS EM TRANSCRIPTASE REVERSA DE HIV-1 CORRELACIONADA COM RESISTêNCIA FENOTìPICA à DROGA". A invenção proporciona novas mutações, combinações de mutações ou perfis mutacionais de genes da transcriptase reversa e/ou protease de HIV-1 correlacionados com a resistência fenotípica a drogas contra o HIV. Mais particularmente, a presente invenção refere-se ao uso de caracterização genotípica de uma população alvo de HIV e a subseq³ente correlação dessa informação à interpretação fenotípica de forma a correlacionar os perfis mutacionais do vírus com a resistência à droga. A invenção também refere-se a métodos de utilização dos perfis mutacionais da invenção em bancos de dados, desenvolvimento de drogas, isto é, projeto de drogas e modificação de drogas, projeto de terapias e tratamentos, gerenciamento clínico e análise diganóstica.
BR0011555-0A 1999-05-28 2000-05-25 Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga BR0011555A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13674399P 1999-05-28 1999-05-28
PCT/EP2000/004915 WO2000073511A1 (en) 1999-05-28 2000-05-25 New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance

Publications (1)

Publication Number Publication Date
BR0011555A true BR0011555A (pt) 2002-02-26

Family

ID=22474176

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011555-0A BR0011555A (pt) 1999-05-28 2000-05-25 Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga

Country Status (12)

Country Link
US (2) US7494768B1 (pt)
EP (1) EP1185712B8 (pt)
JP (1) JP2003501051A (pt)
AT (1) ATE302287T1 (pt)
AU (1) AU783235B2 (pt)
BR (1) BR0011555A (pt)
CA (1) CA2374215C (pt)
DE (1) DE60022036T2 (pt)
ES (1) ES2246859T3 (pt)
MX (1) MXPA01012270A (pt)
NZ (1) NZ516259A (pt)
WO (1) WO2000073511A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
GB9909793D0 (en) * 1999-04-28 1999-06-23 Glaxo Group Ltd Improved assay and reagents therefor
AU783235B2 (en) 1999-05-28 2005-10-06 Virco Bvba New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
JP5156163B2 (ja) 2000-04-18 2013-03-06 ビルコ・ビーブイビーエイ 薬剤耐性の測定方法
AU2631602A (en) 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
AU2002212344B2 (en) * 2000-10-20 2007-05-17 Virco Bvba Establishment of biological cut-off values for predicting resistance to therapy
EP1283272B1 (en) * 2001-08-08 2013-11-13 Janssen R&D Ireland Methods and means for assessing HIV envelope inhibitor therapy
ATE375400T1 (de) * 2002-07-01 2007-10-15 Tibotec Pharm Ltd Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
DE60327768D1 (de) 2002-07-01 2009-07-09 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
CA2490764C (en) 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1605064A1 (en) * 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Variant showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant virus
WO2005121376A2 (en) * 2004-06-07 2005-12-22 Umc Utrecht Holding B.V. Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant
WO2007088201A1 (en) * 2006-02-03 2007-08-09 Virco Bvba Quantitative hiv phenotype or tropism assay
CA2688278A1 (en) 2007-05-25 2008-12-04 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
ES2354785B2 (es) * 2008-09-30 2011-10-13 Universidade De Santiago De Compostela Método de evaluación de resistencia de fenotipos de vih-1 a antirretrovirales.
ES2355027B2 (es) * 2008-09-30 2011-10-13 Universidade De Santiago De Compostela Plásmidos que incluyen la secuencia del vih-1 y sus usos.
WO2010130731A1 (en) * 2009-05-12 2010-11-18 Virco Bvba Hiv-1-c resistance monitoring
JP6268184B2 (ja) 2012-11-26 2018-01-24 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 患患者固有の関連性評価を用いた変異と疾患の関連付けを使用する診断的遺伝子分析
CN110106288B (zh) * 2019-05-13 2021-08-31 昆明理工大学 一种检测hiv-1 pr和rt区耐药突变的引物组、方法及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (en) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogenic substrates for the detection of proteolytic enzyme activity
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
WO1993023574A1 (en) 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
CN1991365A (zh) * 1996-01-26 2007-07-04 沃尔科股份有限公司 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法
JPH11502727A (ja) * 1996-01-26 1999-03-09 イノジェネティックス・ナムローゼ・フェンノートシャップ 逆転写酵素遺伝子における薬剤により誘発された変異の検出方法
JP4183749B2 (ja) 1996-01-29 2008-11-19 ビロロジック・インコーポレーテッド 抗ウィルス剤感受性及び耐性を決定するための組成物及び方法並びに抗ウィルス剤のスクリーニング
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
CA2329140A1 (en) 1998-05-26 1999-12-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
AU4673399A (en) 1998-05-28 1999-12-13 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
WO1999067417A2 (en) 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods
WO1999067428A2 (en) 1998-06-24 1999-12-29 Innogenetics N.V. Method for detection of drug-selected mutations in the hiv protease gene
WO1999067427A1 (en) 1998-06-24 1999-12-29 Virologic, Inc. Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU783235B2 (en) 1999-05-28 2005-10-06 Virco Bvba New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
CA2375905A1 (en) 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
WO2000078994A1 (en) 1999-06-23 2000-12-28 The Penn State Research Foundation Compositions and methods for the quantification of sterol biosynthetic flux
JP5156163B2 (ja) 2000-04-18 2013-03-06 ビルコ・ビーブイビーエイ 薬剤耐性の測定方法
WO2001081624A1 (en) 2000-04-20 2001-11-01 Virco Bvba Method for mutation detection in hiv using pol sequencing
JP4726177B2 (ja) 2000-06-08 2011-07-20 ビルコ・ビーブイビーエイ ニューラルネットワークを使用して治療薬耐性を予測し、そして薬剤耐性の遺伝的基礎を定めるための方法およびシステム
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
EP1322779A4 (en) 2000-09-15 2005-04-20 Virologic Inc MEANS AND METHODS TO TRACE AN ANTIRETROVIRAL PROTEASE INHIBITOR THERAPY, AND THERAPEUTIC GUIDELINES FOR THE TREATMENT OF HIV / AIDS
AU2002212344B2 (en) 2000-10-20 2007-05-17 Virco Bvba Establishment of biological cut-off values for predicting resistance to therapy
AU2631602A (en) 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
IL155780A0 (en) 2000-11-10 2003-12-23 Bioalliance Pharma Novel method for analysing phenotypic characteristics of human imunodeficiency virus (hiv)
BR0207862A (pt) 2001-02-14 2004-06-22 Tibotec Pharm Ltd Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro
US20050214744A1 (en) 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
DE60327768D1 (de) 2002-07-01 2009-07-09 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
CA2490764C (en) 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
AU2003268550A1 (en) 2002-09-06 2004-03-29 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
EP1605064A1 (en) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Variant showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant virus

Also Published As

Publication number Publication date
EP1185712B1 (en) 2005-08-17
CA2374215C (en) 2011-05-24
US8563236B2 (en) 2013-10-22
NZ516259A (en) 2004-02-27
EP1185712B8 (en) 2005-10-19
AU783235B2 (en) 2005-10-06
US7494768B1 (en) 2009-02-24
EP1185712A1 (en) 2002-03-13
JP2003501051A (ja) 2003-01-14
US20090162867A1 (en) 2009-06-25
AU5217500A (en) 2000-12-18
CA2374215A1 (en) 2000-12-07
ATE302287T1 (de) 2005-09-15
WO2000073511A1 (en) 2000-12-07
DE60022036T2 (de) 2006-06-08
MXPA01012270A (es) 2003-06-24
DE60022036D1 (de) 2005-09-22
ES2246859T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Kirkman et al. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance
Orrell et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme
Kozal et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care
Røge et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine
BR9912209A (pt) Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids
Isakov et al. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
Fearnhill et al. A phylogenetic analysis of human immunodeficiency virus type 1 sequences in Kiev: findings among key populations
BR9911600A (pt) Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
Sides et al. HIV-1 subtype diversity in Minnesota
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Precious et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Kleim et al. Antiviral Activity of the Human Immunodeficiency Virus Type 1—Specific Nonnucleoside Reverse Transcriptase Inhibitor HBY 097 Alone and in Combination with Zidovudine in a Phase II Study
Terzi et al. Late HIV seroconversion after non-occupational postexposure prophylaxis against HIV with concomitant hepatitis C virus seroconversion
Palumbo et al. Virologic and Immunologic Response to Nucleoside Reverse-Transcriptase Inhibitor Therapy among Human Immunodeficiency Virus—Infected Infants and Children
BR0111575A (pt) Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Doualla‐Bell et al. Five‐year follow up of genotypic resistance patterns in HIV‐1 subtype C infected patients in Botswana after failure of thymidine analogue‐based regimens
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Abdullaev et al. Features of coronary artery patterns and percutaneous coronary intervention in patients with acute coronary syndrome and stable angina in patients aged below 40 years
Hammond et al. Differential effects of nucleoside reverse transcriptase inhibitor (NRTI) regimens on adipocyte mitochondrial DNA depletion in HIV-infected patients

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.